Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Staels

Showing results (321-330 of 594) with videos related to

Pageof 60
Sort By:
The Journal of Clinical Investigation|April 3, 2002
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response elementThierry Claudel, Ekkehard Sturm, Hélène Duez, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 26, 2005
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalphaAnnelise Genoux, Hélène Dehondt, Audrey Helleboid-Chapman, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 2011
Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophagesGiulia Chinetti-Gbaguidi, Mohamed Amine Bouhlel, Corinne Copin, et al.
Atherosclerosis|May 3, 2011
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASHMorgane Baron, Aurélie S Leroyer, Zouher Majd, et al.
FEBS Letters|May 8, 2010
The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicityIuliana Ristea Popescu, Audrey Helleboid-Chapman, Anthony Lucas, et al.
Hepatology (Baltimore, Md.)|May 13, 2020
Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)Jimmy Vandel, Julie Dubois-Chevalier, Céline Gheeraert, et al.
Shock (Augusta, Ga.)|February 27, 2014
Impact of endotoxin challenge in obese pigsThibault Duburcq, Thomas Hubert, Pierre Saint-Léger, et al.
Journal of Medicinal Chemistry|August 19, 2005
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activityAlessandra Pinelli, Cristina Godio, Antonio Laghezza, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2005
A fully dissociated compound of plant origin for inflammatory gene repressionKarolien De Bosscher, Wim Vanden Berghe, Ilse M E Beck, et al.
Bioorganic & Medicinal Chemistry Letters|April 21, 2009
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variationsCécile Parmenon, Jérôme Guillard, Daniel-Henri Caignard, et al.
Pageof 60

Showing results (321-330 of 594) with videos related to

Sort By:
Pageof 60
The Journal of Clinical Investigation|April 3, 2002
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response elementThierry Claudel, Ekkehard Sturm, Hélène Duez, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 26, 2005
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalphaAnnelise Genoux, Hélène Dehondt, Audrey Helleboid-Chapman, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 31, 2011
Peroxisome proliferator-activated receptor-γ activation induces 11β-hydroxysteroid dehydrogenase type 1 activity in human alternative macrophagesGiulia Chinetti-Gbaguidi, Mohamed Amine Bouhlel, Corinne Copin, et al.
Atherosclerosis|May 3, 2011
PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASHMorgane Baron, Aurélie S Leroyer, Zouher Majd, et al.
FEBS Letters|May 8, 2010
The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicityIuliana Ristea Popescu, Audrey Helleboid-Chapman, Anthony Lucas, et al.
Hepatology (Baltimore, Md.)|May 13, 2020
Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)Jimmy Vandel, Julie Dubois-Chevalier, Céline Gheeraert, et al.
Shock (Augusta, Ga.)|February 27, 2014
Impact of endotoxin challenge in obese pigsThibault Duburcq, Thomas Hubert, Pierre Saint-Léger, et al.
Journal of Medicinal Chemistry|August 19, 2005
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activityAlessandra Pinelli, Cristina Godio, Antonio Laghezza, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 26, 2005
A fully dissociated compound of plant origin for inflammatory gene repressionKarolien De Bosscher, Wim Vanden Berghe, Ilse M E Beck, et al.
Bioorganic & Medicinal Chemistry Letters|April 21, 2009
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variationsCécile Parmenon, Jérôme Guillard, Daniel-Henri Caignard, et al.
Pageof 60